2077.0000 -22.50 (-1.07%)
NSE Sep 16, 2025 15:31 PM
Volume: 578.0K
 

2077.00
-1.07%
BP Wealth
Glenmark Pharma (GPL) earnings came above our estimate. The company posted revenues of Rs 23.6bn with 20% YoY growth which was above our estimate of Rs 22.8bn. EBITDA margin, at 25.1%, was above our estimate of 22.1% due to favorable product mix . Adj.PAT increased at much higher...
Glenmark Pharmaceuticals Ltd. is trading above all available SMAs
More from Glenmark Pharmaceuticals Ltd.
Recommended